KIR molecules: Recent patents of interest for the diagnosis and treatment of several autoimmune diseases, chronic inflammation, and B-cell malignancies

Recent Patents on DNA and Gene Sequences

Volumn 5, Issue 3, 2011, Pages 169-174

  de Re, Valli ^a   Caggiari, Laura ^a   de Zorzi, Mariangela ^a   Toffoli, Giuseppe ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

1 7F9 mAb; Autoimmune diseases; B cell malignancies; CD28nullCD8+ T cells; Chronic inflammation; Diagnosis; HLA; Human leukocyte antigens; Innate immunity; Killer immunoglobulin like receptors; KIR; KIR3DL1 receptor; MAB; Monitoring of disease; Monoclonal antibody; Natural killer cells; Next generation sequencing; NGS; NK; Treatment

Indexed keywords

HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; IPH 2101; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LENALIDOMIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; AUTOIMMUNE DISEASE; B CELL LEUKEMIA; B CELL LYMPHOMA; CHRONIC INFLAMMATION; CHRONIC LYMPHATIC LEUKEMIA; GENE SEQUENCE; GENOTYPE; HAPLOTYPE; HUMAN; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INNATE IMMUNITY; MULTIPLE MYELOMA; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; PATENT; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOTHERAPY; INFLAMMATION; KILLER CELLS, NATURAL; LEUKEMIA, B-CELL; PATENTS AS TOPIC; RECEPTORS, KIR; SEQUENCE ANALYSIS, DNA;

EID: 80054104616     PISSN: 18722156     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221511797636266     Document Type: Article

References (70)

1. Kulkarni S, Martin MP, Carrington M. The Yin and Yang of HLA and KIR in human disease. Semin Immunol 2008; 20 (6): 343-52.
2. Korbel DS, Norman PJ, Newman KC, et al. Killer Ig-like receptor (KIR) genotype predicts the capacity of human KIR-positive CD56dim NK cells to respond to pathogen-associated signals. J Immunol 2009; 182 (10): 6426-34.
3. van Bergen J, Thompson A, Retière C, Trowsdale J, Koning F. Cutting edge: Killer Ig-like receptors mediate missing self recognition in vivo. J Immunol 2009; 182 (5): 2569-72.
4. Yawata M, Yawata N, Draghi M, Partheniou F, Little AM, Parham P. MHC class I specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response. Blood 2008; 112 (6): 2369-80.
5. Yawata M, Yawata N, Draghi M, Little AM, Partheniou F, Parham P. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med 2006; 203 (3): 633-45.
6. Parham P. Killer cell immunoglobulin-like receptor diversity: Balancing signals in the natural killer cell response. Immunol Lett 2004; 92 (1-2): 11-3.
7. Xu J, Vallejo AN, Jiang Y, Weyand CM, Goronzy JJ. Distinct transcriptional control mechanisms of killer immunoglobulin-like receptors in natural killer (NK) and in T cells. J Biol Chem 2005; 280 (25): 24277-85.
8. van Bergen J, Stewart CA, van den Elsen PJ, Trowsdale J. Stuctural and functional differences between the promoters of independently expressed killer cell Ig-like receptors. Eur J Immunol 2005; 35 (7): 2191-9.
9. Trompeter HI, Gomez-Lozano N, Santourlidis S, et al. Three structurally and functionally divergent kinds of promoters regulate expression of clonally distributed killer cell Ig-like receptors (KIR), of KIR2DL4, and of KIR3DL3. J Immunol 2005; 174 (7): 4135-43.
10. Li G, Yu M, Weyand CM, Goronzy JJ. Epigenetic regulation of killer immunoglobulin-like receptor expression in T cells. Blood 2009; 114 (16): 3422-30.
11. Chan HW, Kurago ZB, Stewart CA, et al. DNA methylation maintains allele-specific KIR gene expression in human natural killer cells. J Exp Med 2003; 197 (2): 245-55.
12. van Bergen J, Thompson A, Van Slik AD, Ottenhoff THM, Gussekloo J, Koning F. Phenotypic and functional characterization of CD4 T cells expressing killer Ig-like receptors. J Immunol 2004; 173 (11): 6719-26.
13. Anfossi N, Pascal V, Vivier E, Ugolini S. Biology of T memory type 1 cells. Immunol Rev 2001; 181: 269-78.
14. Mandelboim O, Davis DM, Reyburn HT, et al. Enhancement of Class II-restricted T cell responses by costimulatory NK receptors for Class I MHC proteins. Science 1996; 274 (5295): 2097-2100.
15. Goronzy JJ, Weyand CM. Rheumatoid arthritis. Immunol Rev 2005; 204: 55-73.
16. Moretta A, Biassoni R, Bottino C, et al. Major histocompatibility complex class I-specific receptors on human natural killer and T lymphocytes. Immunol Rev 1997; 155: 105-17.
17. Snyder MR, Muegge LO, Offord C, et al. Formation of the killer Ig-like receptor repertoire on CD4+CD28null T cells. J Immunol 2002; 168 (8): 3839-46.
18. Uhrberg M, Valiante NM, Young NT, Lanier LL, Phillips JH, Parham P. The repertoire of killer cell Ig-like receptor and CD94:NKG2A receptors in T cells: Clones sharing identical alfa beta TCR rearrangement express highly diverse killer cell Ig-like receptor patterns. J Immunol 2001; 166 (6): 3923-32.
19. Gattazzo C, Teramo A, Miorin M, et al. Lack of expression of inhibitory KIR3DL1 receptor in patients with natural killer celltype lymphoproliferative disease of granular lymphocytes. Haematologica 2010; 95 (10): 1722-9.
20. Vallejo AN, Weyand CM, Goronzy JJ. T-cell senescence: A culprit of immune abnormalities in chronic inflammation and persistent infection. Trends Mol Med 2004; 10 (3): 119-24.
21. Warrington KJ, Takemura S, Goronzy JJ, Weyand CM. CD4+,CD28- T cells in rheumatoid arthritis patients combine features of the innate and adaptive immune systems. Arthritis Rheum 2001; 44 (1): 13-20.
22. Ho IC, Glimcher LH. Transcription: Tantalizing times for T cells. Cell 2002; 109 (2 SUPPL. 1): S109-S20.
23. Bentley G, Erlich H, Goodridge D, Ladner M, Trachtenberg E. Determination of KIR haplotypes associated with disease. WO2011035870, 2011.
24. Richardson B. Methods, compositions, and kits for diagnosing, monitoring, and treating disease. WO/2010/048424, 2011.
25. Farag S. Combination therapy to enhance NK cell mediated cytotoxicty. WO/2010/065939, 2011.
26. Valiante NM, Uhrberg M, Shilling HG, et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 1997; 7 (6): 739-51.
27. Litwin V, Gumperz J, Parham P, Phillips JH, Lanier LL. NKB1: A natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules. J Exp Med 1994; 180 (2): 537-43.
28. Marsh SG, Parham P, Dupont B, et al. Killer.cell immunoglobulinlike receptor (KIR) nomenclature report, 2002. Tissue Antigens 2003; 62 (1): 79-86.
29. Trowsdale J. Genetic and functional relationships between MHC and NK receptor genes. Immunity 2001; 15 (3): 363-74.
30. Parham P. Immunogenetics of killer cell immunoglobulin-like receptors. Mol Immunol 2005; 42 (4 SPEC. ISS.): 459-62.
31. Single RM, Martin MP, Gao X, et al. Global diversity and evidence for coevolution of KIR and HLA. Nat Genet 2007; 39 (9): 1114-9.
32. Martin MP, Single RM, Wilson MJ, Trowsdale J, Carrington M. KIR haplotypes defined by segregation analysis in 59 Centre d'Etude Polymorphisme Humain (CEPH) families. Immunogenetics 2008; 60 (12): 767-74.
33. Snyder MR, Nakajima T, Leibson PJ, Weyand CM, Goronzy JJ. Stimulatory killer Ig-like receptors modulate T cell activation through DAP12-dependent and DAP12-independent mechanisms. J Immunol 2004; 173 (6): 3725-31.
34. Carr WH, Rosen DB, Arase H, Nixon DF, Michaelsson J, Lanier LL. Cutting edge: KIR3DS1, a gene implicated in resistance to progression to AIDS, encodes a DAP12-associated receptor expressed on NK cells that triggers NK cell activation. J Immunol 2007; 178 (2): 647-51.
35. Gardiner CM, Guethlein LA, Shilling HG, et al. Different NK cell surface phenotypes defined by the DX9 antibody are due to KIR3DL1 gene polymorphism. J Immunol 2001; 166 (5): 2992-3001.
36. O'Connor GM, Guinan KJ, Cunningham RT, Middleton D, Parham P, Gardiner CM. Functional polymorphism of the KIR3DL1/S1 receptor on human NK cells. J Immunol 2007; 178 (1): 235-41.
37. Thananchai H, Gillespie G, Martin MP, et al. Cutting edge: Allelespecific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B. J Immunol 2007; 178 (1): 33-7.
38. Ansorge WJ. Next-generation DNA sequencing techniques. New Biotechnol 2009; 25 (4): 195-203.
39. Su Z, Ning B, Fang H, et al. Next-generation sequencing and its applications in molecular diagnostics. Expert Rev Mol Diagn 2011; 11 (3): 333-43.
40. Williams R, Peisajovich SG, Miller OJ, Magdassi S, Tawfik DS, Griffiths AD. Amplification of complex gene libraries by emulsion PCR. Nat Methods 2006; 3 (7): 545-50.
41. Holcomb CL, Höglund B, Anderson MW, et al. A multi-site study using high-resolution HLA genotyping by next generation sequencing. Tissue Antigens 2011; 77 (3): 206-17.
42. Margulies M, Egholm M, Altman WE, et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature 2005; 437 (7057): 376-80.
43. Basu D, Liu Y, Wu A, et al. Stimulatory and inhibitory killer Iglike receptor molecules are expressed and functional on lupus T cells. J Immunol 2009; 183 (5): 3481-7.
44. Li G, Yu M, Weyand CM, Goronzy JJ. Epigenetic regulation of killer immunoglobulin-like receptor expression in T cells. Blood 2009; 114 (16): 3422-30.
45. Liu Y, Chen Y, Richardson B. Decreased DNA methyltransferase levels contribute to abnormal gene expression in senescent CD4+CD28- T cells. Clin Immunol 2009; 132 (2): 257-65.
46. Liu Y, Kuick R, Hanash S, Richardson B. DNA methylation inhibition increases T cell KIR expression through effects on both promoter methylation and transcription factors. Clin Immunol 2009; 130 (2): 213-24.
47. Trompeter HI, Gomez-Lozano N, Santourlidis S, et al. Three structurally and functionally divergent kinds of promoters regulate expression of clonally distributed killer cell Ig-like receptors (KIR), of KIR2DL4, and of KIR3DL3. J Immunol 2005; 174 (7):
48. C41h3a5n- 4H3W., Kurago ZB, Stewart CA, et al. DNA methylation maintains allele-specific KIR gene expression in human natural killer cells. J Exp Med 2003; 197 (2): 245-55.
49. Pohl NM, Tong C, Fang W, Bi X, Li T, Yang W. Transcriptional regulation and biological functions of selenium-binding protein 1 in colorectal cancer in vitro and in nude mouse xenografts. PLoS ONE 2009; 4 (11): e7774.
50. Michel F, Attal-Bonnefoy G, Mangino G, Mise-Omata S, Acuto O. CD28 as a molecular amplifier extending TCR ligation and signaling capabilities. Immunity 2001; 15 (6): 935-45.
51. Effros RB, Boucher N, Porter V, et al. Decline in CD28+ T cells in centenarians and in long-term T cell cultures: A possible cause for both in vivo and in vitro immunosenescence. Exp Gerontol 1994; 29 (6): 601-9.
52. Posnett DN, Sinha R, Kabak S, Russo C. Clonal populations of T cells in normal elderly humans: The T cell equivalent to 'benign monoclonal gammapathy'. J Exp Med 1994; 179 (2): 609-18.
53. Choremi-Papadopoulou H, Viglis V, Gargalianos P, Kordossis T, Theodoraki A, Kosmidis J. Downregulation of CD28 surface antigen on CD4+ and CD8+ T lymphocytes during HIV-1 infection. J Acquir Immune Defic Syndr 1994; 7 (3): 245-53.
54. Dolfi DV, Duttagupta PA, Boesteanu AC, et al. Dendritic cells and CD28 costimulation are required to sustain virus-specific CD8+ T cell responses during the effector phase in vivo. J Immunol 2011; 186 (8): 4599-608.
55. Akbar AN, Henson SM. Are senescence and exhaustion intertwined or unrelated processes that compromise immunity? Nat Rev Immunol 2011; 11 (4): 289-95.
56. Vallejo AN, Schirmer M, Weyand CM, Goronzy JJ. Clonality and longevity of CD4+CD28 (null) T cells are associated with defects in apoptotic pathways. J Immunol 2000; 165 (11): 6301-07.
57. Schmidt D, Goronzy JJ, Weyand CM. CD4+ CD7- CD28- T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity. J Clin Invest 1996; 97 (9): 2027-37.
58. Michel JJ, Turesson C, Lemster B, et al. CD56-expressing T cells that have features of senescence are expanded in rheumatoid arthritis. Arthritis Rheum 2007; 56 (1): 43-57.
59. Moosig F, Csernok E, Wang G, Gross WL. Costimulatory molecules in Wegener's granulomatosis (WG): Lack of expression of CD28 and preferential up-regulation of its ligands B7-1 (CD80) and B7-2 (CD86) on T cells. Clin Exp Immunol 1998; 114 (1): 113-8.
60. Garcia De Tena J, Manzano L, Leal JC, San Antonio E, Sualdea V, Alvarez-Mon M. Active Crohn's disease patients show a distinctive expansion of circulating memory CD4+CD45RO+CD28null T cells. J Clin Immunol 2004; 24 (2): 185-96.
61. Kobayashi T, Okamoto S, Iwakami Y, et al. Exclusive increase of CX3CR1+CD28-CD4+ T cells in inflammatory bowel disease and their recruitment as intraepithelial lymphocytes. Inflamm Bowel Dis 2007; 13 (7): 837-46.
62. Duftner C, Goldberger C, Falkenbach A, et al. Prevalence, clinical relevance and characterization of circulating cytotoxic CD4+CD28- T cells in ankylosing spondylitis. Arthritis Res Ther 2003; 5 (5): R292-R300.
63. Zal B, Kaski JC, Arno G, et al. Heat-Shock Protein 60-Reactive CD4+CD28null T Cells in Patients with Acute Coronary Syndromes. Circulation 2004; 109 (10): 1230-35.
64. Miyazaki Y, Iwabuchi K, Kikuchi S, et al. Expansion of CD4+CD28- T cells producing high levels of interferon-+?? in peripheral blood of patients with multiple sclerosis. Mult Scler 2008; 14 (8): 1044-55.
65. La Cava A. Lupus and T Cells. Lupus 2009; 18 (3): 196-201.
66. Koehler H, Kofler D, Hombach A, Abken H. CD28 costimulation overcomes transforming growth factor-+??-mediated repression of proliferation of redirected human CD4+ and CD8 + T cells in an antitumor cell attack. Cancer Res 2007; 67 (5): 2265-73.
67. Romagné F, André P, Spee P, et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 2009; 114 (13): 2667-77.
68. Alici E. IPH-2101, a fully human anti-NK-cell inhibitory receptor mAb for the potential treatment of hematological cancers. Curr Opin Mol Ther 2010; 12 (6): 724-33
69. Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 2008; 26 (9): 1544-52.
70. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: A target for new treatment strategies. Blood 2009; 114 (16): 3367-75.